Nebilet (Nebivolol)

Nebivolol, the active ingredient in Nebilet, is a beta blocker presented as an oral tablet for oral use. It selectively lowers blood pressure and improves vascular function in adults with hypertension and may be used in certain cases of heart failure. Nebivolol works by blocking β1‑adrenergic receptors while also promoting nitric‑oxide mediated vasodilation.

GNH USA supplies Nebilet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebilet is a beta‑blocker that acts on the cardiovascular system to manage elevated blood pressure and related conditions.

Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension. Heart failure: improves cardiac output and symptoms in patients with heart failure with reduced ejection fraction. Cardiovascular risk management: contributes to overall risk reduction when combined with other antihypertensive therapies.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general tiredness. - Bradycardia: slower than normal heart rate. - Nausea or mild gastrointestinal upset. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to fainting. - Bronchospasm in patients with asthma or COPD. - Allergic reactions such as rash, itching, or angioedema. - Hepatic dysfunction or elevated liver enzymes. - Cardiac failure exacerbation in susceptible individuals.

Before initiating Nebilet, clinicians should evaluate patient history and monitor for specific concerns.

Assess cardiovascular status: verify baseline blood pressure and heart rate. Monitor heart rate: watch for excessive bradycardia during therapy. Use caution in asthma/COPD: β1‑selectivity reduces but does not eliminate risk of bronchospasm. Adjust in renal/hepatic impairment: dose may need modification in reduced function. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Store at ambient temperature: keep in the original pack, protect from moisture.

Nebilet can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Other beta‑blockers: additive cardiac depression. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV block. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): elevated nebivolol plasma levels.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance hypotensive effect. - ACE inhibitors or ARBs: combined blood pressure lowering requires monitoring. - NSAIDs: can blunt antihypertensive response. - Digoxin: may increase risk of bradyarrhythmias.